Newsroom

Discover the latest news and updates from Causaly.

Featured news

news

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

Andrew Taylor
July 13, 2023

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Read more
news

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Yiannis Kiachopoulos
May 19, 2021

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

Read more

Further reading

news

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

Andrew Taylor
July 13, 2023

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Read more
news

Causaly announces ISO 27001 certification

Andrew Taylor
June 28, 2022

We are proud to announce a major milestone for Causaly: successfully passing ISO 27001 certification.

Read more
news

Causaly announces the appointment of Chris Tunnell as SVP Global Sales

Andrew Taylor
May 13, 2022

Causaly, a world leader in R&D analytics that allows researchers and specialists to navigate the intricate landscape of research, today announced the appointment of Chris Tunnell as SVP of Global Sales

Read more
news

Alex Meissner joins Causaly as VP Strategy & Business Operations

Yiannis Kiachopoulos
January 10, 2022

Causaly, a leader in R&D Analytics that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, announced today that it has added Alex Meissner to the management team as Vice President for Strategy & Business Operations

Read more
news

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Yiannis Kiachopoulos
May 19, 2021

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

Read more
news

Covid-19: Causaly partners with UCL to accelerate coronavirus research

Yiannis Kiachopoulos
April 21, 2020

At Causaly we’re excited to announce a new partnership with University College London (UCL) to help accelerate research into the pandemic.

Read more
© Causaly. All rights reserved.